refractory to treatment. 7 It has been reported that the Wnt/β-catenin signalling pathway contributes to the development of leukaemia stem cells (LSCs) in CML and plays an important role in the survival and renewal of CML cells. 8, 9 Studies have shown that the suppression of β-catenin results in CML cells becoming more susceptible to imatinib. 10 In addition to the potential role of the Wnt/β-catenin signalling pathway and its downstream effects as a potential target for treatment of human leukaemia, upstream regulatory signal pathways may also be attractive future targets for treatment. Funato et al 11 have identified the activation of Wnt signalling through oxidative stress, while cellular defence against reactive oxygen species (ROS) has been shown to be mediated by β-catenin. 12 Similar to Wnt signalling, the formation of ROS plays an important role in carcinogenesis, specifically in the molecular regulation programmed cell death, or apoptosis. 13 Mitochondria are the major source and target of ROS, and abnormal ROS levels will induce the apoptosis of cancer cells via the mitochondrial pathway. 14 Mitochondria have a central role in maintaining cell viability, and in apoptosis there is a loss of mitochondrial membrane potential (MMP), mitochondrial outer membrane permeabilization followed by the release of proteins including cytochrome c, and Smac/ DIABLO into the cytosol with the accumulation of cytosolic effector proteases (caspases). 15 Because the abnormal regulation of apoptosis is an important component of cancer development, drugs that induce tumour cell apoptosis and prevent uncontrolled cell division may be effective in many forms of malignancy, including leukaemia. 16 The novel pyrazoline derivative, N-(4-hydroxybenzyl)-1,3,4-triphenyl -4,5-dihydro-1H-pyrazole-5-carboxamide (BHX), designed and synthesized previously, has been described to block the canonical Wnt/β-catenin signalling pathway, and has been reported to exhibit cytotoxic effects in multiple solid tumour cell lines. [17] [18] [19] However, the anti-proliferative effects of BHX on leukaemia cells have not been previously investigated. The purpose of this study was to evaluate the effects of BHX on human CML cells in vitro and to elucidate the underlying molecular mechanism.
| MATERIALS AND METHODS

| Cell culture and reagents
The K562 cells were maintained in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/ mL streptomycin at 37°C in 5% CO 2 in a humidified incubator. RPMI 1640, FBS, penicillin and streptomycin were purchased from Gibco (Gaithersburg, MD, USA). Primary antibodies against β-catenin, cjun, c-myc, cyclin D1, Lamin B and GAPDH were obtained from Cell
Signalling Technology (Danvers, MA, USA). 
| Cell proliferation assay
| Cellular uptake
Pyrazolines, including BHX, are fluorophores that emit fluorescence when viewed under UV light. After treating the cells with BHX for increasing time points at 37°C, the medium was removed and the cells were rinsed 3 times with PBS to remove the extracellular BHX. An
HCl/DMSO solution (0.04 mol/L, 100 μL) was added to lyse the cells, and the intensity of the fluorescence of the BMX in the lysate was determined by the use of a fluorescence SpectraMax M5 microplate reader (Molecular Devices) with the excitation and emission wavelengths set at 350 and 460 nm, respectively.
| Apoptosis and cell cycle assay
For apoptosis assay, cells were seeded into 6-well plates and increas- 
| Measurement of ROS generation, MMP and intracellular Ca
2+
The effect of BHX on the intracellular ROS generation was monitored by and FL2 channel (red channel), respectively. Intracellular Ca 2+ was detected using 5 μmol/L of Fluo-3 acetoxymethyl ester derivative.
| Caspase activity assay
The activity of caspase-3 and caspase-9 was determined using a col- 
| ATP-luciferase assay
Intracellular ATP levels were measured using the firefly luciferasebased ATP assay kit (Beyotime). Briefly, after BHX treatment, the K562 cells were centrifuged at 12 000 g for 5 minutes. In 96-well plates, 100 μL of each supernatant was mixed with 100 μL ATP working dilution of detection solution. Luminance was measured in relative luminescence units with an Epoch microplate reader (BioTek) and data were normalized to total cell protein.
| Western blot analysis
Protein was lysed from the treated cells by SDS lysis buffer.
Similarly, nuclear extracts were prepared by using NE-PER nuclear extraction reagents (Thermo Fisher, Waltham, MA, USA). The protein was then transferred onto polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). The membranes were then incubated with antibodies against GAPDH, Lamin B, β-catenin, c-jun, c-myc and cyclin D1 (1:1000 dilution), followed by incubation with IRDyeconjugated anti-rabbit or anti-mouse IgG secondary antibody (1:1000 dilution). Blot images were visualized and recorded with an Odyssey LI-COR infrared imaging system (LI-COR, Lincoln, NE, USA).
| PCR analysis
Total RNA from K562 cells was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA, USA). Synthesis of cDNA was done by using a RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). β-Catenin was amplified by a standard PCR protocol using 5′-CATCATCGTGAGGGCTTACTG-3′ as forward primer, and 5′-TGAAGGCAGTCTGTCGTAATAG-3′ as reverse primer.
The reaction mixtures were heated at 95°C for 10 minutes, followed by 30 cycles of 94°C for 30 seconds, 58°C for 30 seconds, 72°C for 20 seconds and a final extension at 72°C for 5 minutes.
Subsequently, PCR products were electrophoresed through 1.5%
agarose gel and then subjected to a gel/fluorescence image analysis system for scanning. GAPDH was selected as the endogenous control in the assay. The bone marrow cells were collected as previously described with slight modification. 20 The femoral bones were separated, briefly 
| Animal studies
| Statistical analysis
All data were presented as mean ± SD. Statistical analysis was performed using a 2-tailed t test and analysis of variance (ANOVA). A value of P < .05 was considered statistically significant.
| RESULTS
| Cellular uptake of BHX
The chemical structure of BHX is presented in Figure 1A . BHX has an absorption peak at wavelength 350 nm ( Figure 1B 
| Morphology of BHX-treated cells
The morphological changes of K562 cells induced by BHX were depicted in Figure 2B . Cells treated with BHX showed the characteristics of apoptosis, including cell shrinkage, cell fragmentation and perinuclear clumping of condensed chromatin. The morphological changes were much more noticeable after incubation of K562 cells with relatively high concentrations of BHX.
| BHX arrested the cell cycle and induced apoptosis
As shown in Figure 3A , BHX treatment arrested the K562 cell cycle at the G0/G1 phase and resulted in a decrease in the number of cells To further investigate how BHX regulates cell cycle, we detected
Wnt pathway downstream target genes c-jun, c-myc and cyclin D1
by Western blot. As depicted in Figure 3C , the expression of related proteins was downregulated in a dose-dependent manner.
| BHX-induced caspase activation
As illustrated in Figure 4A , the activity of caspase-3 and caspase-9 were increased in a concentration-dependent manner following BHX treatment. The caspase-3 activity increased to 1.18 ± 0.09, 
| BHX inhibited the transcription of β-catenin
The results of Western blotting reviewed that the expression of β-catenin in the nucleus was downregulated after BHX treatment ( Figure 7A ). What is more, the expression level of total β-catenin after BHX treatment was also downregulated. However, compared with the control group, the expression of p-β-catenin did not increase. In contrast, BHX slightly decreased the p-β-catenin expression ( Figure 7B ). Further, we examined β-catenin at the transcriptional level by PCR, and the results in Figure 7C showed that the mRNA level of β-catenin was significantly decreased by 50 μmol/L BHX treatment (P < .05).
| Effect of BHX on peripheral blood cells, BMNC and organ index
There were no unexpected deaths after BHX treatment. /femur, respectively. And the quantities of WBC were significantly reduced after BHX treatment (80 or 160 mg/kg, P < .05). However, no statistically significant differences were found in the organ index between the control group and the BHX-treated group (Table 2) .
| DISCUSSION
In the present study, BHX suppressed K562 cell proliferation in a dose-dependent manner and induced apoptosis and G0/G1 phase arrest. K562 cells treated with BHX showed morphological characteristics of apoptosis, which was associated with downregulation of MMP, activation of caspase-3 and caspase-9, generation of intracellular ROS, and elevation of Ca 2+ in K562 cells. In BHX-treated cells, Each assay was repeated in triplicate; data were expressed as mean ± SD #P < .05 and ##P < .01 compared with the control group F I G U R E 7 Effect of BHX on the protein expression of β-catenin in the nucleus (A), total β-catenin and p-β-catenin (B). Effect of BHX on the mRNA expression of β-catenin (C). K562 cells were treated with different concentrations of BHX for 24 h and the protein expression of p-β-catenin, β-catenin in the nucleus and total β-catenin was determined by Western blot analysis. mRNA expression of β-catenin was determined by PCR. GAPDH was used as a loading control ATP levels were decreased, the expression of β-catenin in the nucleus, total β-catenin and p-β-catenin was decreased, and the expression of cell cycle-related proteins c-jun, c-myc and cyclin D1 was decreased.
Co-treatment of BHX with the reducing agent, NAC, decreased the effect of BHX-induced G0/G1 phase arrest and caspase activation.
The PCR analysis showed that BHX had inhibitory effect on the β-catenin mRNA level. The findings are supported by previous studies and, as the published literature shows, they have implications for future treatment approaches for human CML.
The Wnt/β-catenin signalling pathway is known to play an important role in the pathogenesis and progression of CML. 21 The deletion of β-catenin in mice has been reported to cause a reduction in the risk of CML induced by Bcr-Abl. 22 Increased activity of the Wnt/β-catenin pathway has been shown to correlate with a poor patient response to imatinib and LSC transformation in "blast crisis" CML. 23 The effect of BHX on leukaemia cells and the underlying molecular mechanisms of action have remained unclear, until the present study demonstrated that BHX inhibited the growth of K562 cells by inducing apoptosis and G0/G1 arrest. To our knowledge, this is the first report of the possible effect of BHX in CML.
Furthermore, this study found that BHX treatment decreased the expression of β-catenin and the protein products of the Wnt target genes c-myc, c-jun and cyclin D1 in the G1-S transition, which resulted in cell cycle arrest during the G0/G1 phase, a finding which is supported by a previous study. 24 Accumulated β-catenin travels to the nucleus and activates the Wnt signalling pathway. In the absence of Wnt signalling, the level of β-catenin remained low through the degradation of cytoplasmic β-catenin, which is targeted for phosphorylation by CK1-α at the Ser45 site, followed by phosphorylation by GSK3-β at Ser33, Ser37 and Thr41. 25 Therefore, we detected the protein levels of p-β-catenin at the Ser45/Thr41 site after BHX treatment. However, the p-β-catenin protein level was slightly downregulated. Hence, BHX reduced the expression of β-catenin not by blocking the Wnt signalling pathway. PCR experiment revealed that β-catenin mRNA levels decreased, implying that the synthesis of β-catenin was reduced. Hence, β-catenin transcription and translation was downregulated, reducing β-catenin protein levels in the cytoplasm, and ultimately inhibiting the Wnt signalling pathway. Thus, the total amount of β-catenin was reduced, and p-β-catenin level also was lowered slightly.
Apoptosis, or programmed cell death, may occur through an intrinsic cell death receptor-mediated pathway or an extrinsic mitochondria-mediated pathway. 26 Apoptotic cell death serves as a natural barrier to cancer development, and may be an effective target to preventing the progression of malignancy. 27 The mitochondrial pathway is generated by internal signals arising within the cell, including ROS, reactive nitrogen species, hormones, cell-cell interactions, growth factors, antigens and chemotherapeutics. 28 The present study illustrated that BHX decreased the level of MMP in K562 cells in a dose-dependent manner. The loss of MMP is recognized as a pivotal event in early mitochondrial-dependent apoptosis, resulting in the release of cytochrome c from the mitochondria to the cytoplasm, activation of caspase-9, leading to the downstream activation of caspase-3. 29, 30 Caspases are aspartate-specific cysteine proteases that execute selective cleavage of key cellular components with a key role in regulating biological processes, including apoptosis. 31, 32 Induction of apoptosis in cells leads to the activation of a family of caspases including effector caspase-3, -6, -7 and initiator caspase-8, -9 and-10. 33 The active form of caspase-9 activates caspase-3, resulting in the disintegration of cytoskeletal and nuclear proteins. 34 The finding in this study that increased activities of caspase-3 and caspase-9 in K562 cells following BHX treatment supported the mitochondria-dependent activation of the caspase cascade.
35
ROS play important roles in cell signalling and homeostasis, and are chemically reactive, oxygen-containing molecules. 36 Funato et al 11 identified the activation of Wnt signalling through oxidative stress, while cellular defence against ROS is mediated by β-catenin. 12 Large intracellular ROS levels could attack biological molecules, breaking the redox balance of the cells, leading to DNA damage and cell apoptosis through downstream signalling pathways, thereby playing a role in carcinogenesis. 37 In the current study, following BHX treatment, ROS levels increased dramatically, which indicated that BHX is a ROS-sensitive drug and the effect of leukaemic cell apoptosis requires the ROS signalling pathway. 35 High levels of ROS could result in oxidative damage to mitochondrial proteins and is sufficient to trigger mitochondrial dysfunction, including the ability to synthesize ATP. 38, 39 Therefore, ATP levels were measured, and showed a dose-dependent decrease in ATP levels following BHX treatment, indicating that BHX can affect cell viability by inhibiting the respiratory cycle. 40 Mitochondrial modulation of Ca 2+ signalling and intracellular Ca 2+ is produced during apoptosis and acts as a second messenger. 41 Furthermore, intracellular Ca 2+ can be sequestered in mitochondria to promote oxidative phosphorylation, but Ca 2+ overload can trigger mitochondria depolarization and leads to the release of apoptosis promoting factors. 42 The elevation of Ca 2+ demonstrated in this study was associated with mitochondrial-mediated apoptosis triggered by BHX. Although the detailed molecular mechanisms of mitochondrial dysfunction remain to be further elucidated, these results demonstrated that mitochondrial dysfunction was induced by BHX.
In summary, these findings support a role for BHX-induced mitochondrial-dependent apoptosis and G0/G1 phase in K562 human myelogenous leukaemia cells in vitro connected to the Wnt/β-catenin signalling pathway. This study suggested that BHX should be evaluated further as a potential treatment for human leukaemia.
